$ADCT
ADC Therapeutics SA Stock $adct

$adct Overview Financials Valuation SEC Filings Company Website

2024 Q1 Form 10-K Financial Statement

#000162828024010843 Filed on March 13, 2024

Income Statement

Concept	2024 Q1	2023 Q4	2023
Revenue	$18.05M	$16.79M	$69.56M
YoY Change	-4.94%	-75.94%	-66.86%
Cost Of Revenue	$2.510M	$1.215M	$2.529M
YoY Change	325.42%	96.6%	21.65%
Gross Profit	$15.54M	$15.58M	$67.03M
YoY Change	-15.54%	-77.49%	-67.75%
Gross Profit Margin	86.1%	92.76%	96.36%
Selling, General & Admin	$23.42M	$25.22M	$105.9M
YoY Change	-23.04%	-48.34%	-24.71%
% of Gross Profit	150.69%	161.94%	157.97%
Research & Development	$25.74M	$30.33M	$127.1M
YoY Change	-33.25%	-37.17%	-32.34%
% of Gross Profit	165.57%	194.74%	189.66%
Depreciation & Amortization	$331.0K	-$914.0K	$1.187M
YoY Change	-52.31%	-258.68%	-49.01%
% of Gross Profit	2.13%	-5.87%	1.77%
Operating Expenses	$49.16M	$55.55M	$233.0M
YoY Change	-29.15%	-30.4%	24.01%
Operating Profit	-$33.61M	-$39.98M	-$166.0M
YoY Change	-34.06%	275.7%	-932.8%
Interest Expense	$12.50M	-$9.618M	$46.33M
YoY Change	-240.22%	-3.67%	478.63%
% of Operating Profit
Other Income/Expense, Net	-$12.14M	$9.724M	-$29.43M
YoY Change	-8773.57%	8505.31%	-8344.54%
Pretax Income	-$45.80M	-$39.87M	-$7.888M
YoY Change	-23.27%	97.48%	-94.9%
Income Tax	$200.0K	$43.17M	$39.11M
% Of Pretax Income
Net Earnings	-$46.61M	-$85.03M	-$240.1M
YoY Change	-21.57%	251.99%	54.08%
Net Earnings / Revenue	-258.16%	-506.44%	-345.11%
Basic Earnings Per Share	-$0.56		-$2.94
Diluted Earnings Per Share	-$0.56	-$1.03	-$2.94
COMMON SHARES
Basic Shares Outstanding	82.53M shares		81.71M shares
Diluted Shares Outstanding	82.55M shares		81.71M shares

Balance Sheet

Concept	2024 Q1	2023 Q4	2023
SHORT-TERM ASSETS
Cash & Short-Term Investments	$234.3M	$278.6M	$278.6M
YoY Change	-24.56%	-14.66%	-14.66%
Cash & Equivalents	$234.3M	$278.6M	$278.6M
Short-Term Investments
Other Short-Term Assets	$16.74M	$16.33M	$16.33M
YoY Change	-38.4%	-41.75%	-38.73%
Inventory	$16.00M	$16.18M	$16.18M
Prepaid Expenses
Receivables	$23.19M	$25.18M	$25.18M
Other Receivables	$0.00	$0.00	$0.00
Total Short-Term Assets	$290.2M	$336.3M	$336.3M
YoY Change	-23.63%	-24.6%	-24.6%
LONG-TERM ASSETS
Property, Plant & Equipment	$5.785M	$5.622M	$16.13M
YoY Change	-63.17%	-43.67%	61.64%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments	$930.0K	$1.647M	$1.647M
YoY Change	-96.85%	-94.71%	-94.71%
Other Assets	$986.0K	$711.0K	$711.0K
YoY Change	-96.58%	-97.43%	-97.43%
Total Long-Term Assets	$17.76M	$18.49M	$18.49M
YoY Change	-79.74%	-77.76%	-77.76%
TOTAL ASSETS
Total Short-Term Assets	$290.2M	$336.3M	$336.3M
Total Long-Term Assets	$17.76M	$18.49M	$18.49M
Total Assets	$308.0M	$354.8M	$354.8M
YoY Change	-34.15%	-32.95%	-32.95%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$14.32M	$15.57M	$15.57M
YoY Change	64.65%	26.05%	26.05%
Accrued Expenses	$48.67M	$50.63M	$50.63M
YoY Change		-26.07%	210.52%
Deferred Revenue
YoY Change
Short-Term Debt	$0.00	$0.00	$0.00
YoY Change		-100.0%
Long-Term Debt Due		$1.467M	$1.467M
YoY Change		-89.19%	-89.19%
Total Short-Term Liabilities	$62.99M	$67.67M	$67.67M
YoY Change	-22.32%	-31.62%	-31.62%
LONG-TERM LIABILITIES
Long-Term Debt	$423.2M	$426.5M	$426.5M
YoY Change	30.42%	34.9%	34.9%
Other Long-Term Liabilities	$6.524M	$8.879M	$8.879M
YoY Change	-73.24%	-64.94%	-64.94%
Total Long-Term Liabilities	$6.524M	$8.879M	$435.4M
YoY Change	-98.13%	-97.4%	27.49%
TOTAL LIABILITIES
Total Short-Term Liabilities	$62.99M	$67.67M	$67.67M
Total Long-Term Liabilities	$6.524M	$8.879M	$435.4M
Total Liabilities	$502.4M	$503.0M	$503.0M
YoY Change	16.84%	14.21%	14.21%
SHAREHOLDERS EQUITY
Retained Earnings	-$1.382B	-$1.335B
YoY Change		21.91%
Common Stock	$7.312M	$7.312M
YoY Change		0.0%
Preferred Stock
YoY Change
Treasury Stock (at cost)	$502.0K	$541.0K
YoY Change		-20.32%
Treasury Stock Shares
Shareholders Equity	-$194.4M	-$148.2M	-$148.2M
YoY Change
Total Liabilities & Shareholders Equity	$308.0M	$354.8M	$354.8M
YoY Change	-34.15%	-32.95%	-32.95%

Cashflow Statement

Concept	2024 Q1	2023 Q4	2023
OPERATING ACTIVITIES
Net Income	-$46.61M	-$85.03M	-$240.1M
YoY Change	-21.57%	251.99%	54.08%
Depreciation, Depletion And Amortization	$331.0K	-$914.0K	$1.187M
YoY Change	-52.31%	-258.68%	-49.01%
Cash From Operating Activities	-$44.10M	-$33.07M	-$118.7M
YoY Change	198.52%	-36.52%	-13.24%
INVESTING ACTIVITIES
Capital Expenditures	$531.0K	$327.0K	$3.216M
YoY Change	-47.74%	179.49%	39.95%
Acquisitions
YoY Change
Other Investing Activities
YoY Change
Cash From Investing Activities	-$531.0K	-$527.0K	-$3.216M
YoY Change	-47.74%	350.43%	28.23%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	$356.0K	1.639M	$73.88M
YoY Change	-281.63%	-166.95%	-12557.84%
NET CHANGE
Cash From Operating Activities	-$44.10M	-33.07M	-$118.7M
Cash From Investing Activities	-$531.0K	-527.0K	-$3.216M
Cash From Financing Activities	$356.0K	1.639M	$73.88M
Net Change In Cash	-$44.27M	-31.96M	-$48.03M
YoY Change	176.98%	-41.53%	-65.67%
FREE CASH FLOW
Cash From Operating Activities	-$44.10M	-$33.07M	-$118.7M
Capital Expenditures	$531.0K	$327.0K	$3.216M
Free Cash Flow	-$44.63M	-$33.40M	-$121.9M
YoY Change	182.68%	-36.03%	-12.36%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
CY2023	dei	Amendment Flag AmendmentFlag	false
CY2023	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2023
CY2023	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	FY
CY2023	dei	Entity Central Index Key EntityCentralIndexKey	0001771910
CY2023	us-gaap	Defined Benefit Plan Net Periodic Benefit Cost Credit Excluding Service Cost Statement Of Income Or Comprehensive Income Extensible List DefinedBenefitPlanNetPeriodicBenefitCostCreditExcludingServiceCostStatementOfIncomeOrComprehensiveIncomeExtensibleList	http://fasb.org/us-gaap/2023#CostsAndExpenses
CY2022	us-gaap	Defined Benefit Plan Net Periodic Benefit Cost Credit Excluding Service Cost Statement Of Income Or Comprehensive Income Extensible List DefinedBenefitPlanNetPeriodicBenefitCostCreditExcludingServiceCostStatementOfIncomeOrComprehensiveIncomeExtensibleList	http://fasb.org/us-gaap/2023#CostsAndExpenses
CY2023	dei	Document Annual Report DocumentAnnualReport	true
CY2023	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
CY2023	dei	Document Transition Report DocumentTransitionReport	false
CY2023	dei	Entity File Number EntityFileNumber	001-39071
CY2023	dei	Entity Registrant Name EntityRegistrantName	ADC Therapeutics SA
CY2023	dei	Entity Incorporation State Country Code EntityIncorporationStateCountryCode	V8
CY2023	dei	Entity Address Address Line1 EntityAddressAddressLine1	Biopôle
CY2023	dei	Entity Address Address Line2 EntityAddressAddressLine2	Route de la Corniche 3B
CY2023	dei	Entity Address Postal Zip Code EntityAddressPostalZipCode	1066
CY2023	dei	Entity Address City Or Town EntityAddressCityOrTown	Epalinges
CY2023	dei	Entity Address Country EntityAddressCountry	CH
CY2023	dei	Country Region CountryRegion	41
CY2023	dei	City Area Code CityAreaCode	21 653
CY2023	dei	Local Phone Number LocalPhoneNumber	02 00
CY2023	dei	Security12g Title Security12gTitle	Common Shares, par value CHF 0.08 per share
CY2023	dei	Trading Symbol TradingSymbol	ADCT
CY2023	dei	Security Exchange Name SecurityExchangeName	NYSE
CY2023	dei	Entity Well Known Seasoned Issuer EntityWellKnownSeasonedIssuer	No
CY2023	dei	Entity Voluntary Filers EntityVoluntaryFilers	No
CY2023	dei	Entity Current Reporting Status EntityCurrentReportingStatus	Yes
CY2023	dei	Entity Interactive Data Current EntityInteractiveDataCurrent	Yes
CY2023	dei	Entity Filer Category EntityFilerCategory	Accelerated Filer
CY2023	dei	Entity Small Business EntitySmallBusiness	true
CY2023	dei	Entity Emerging Growth Company EntityEmergingGrowthCompany	false
CY2023	dei	Icfr Auditor Attestation Flag IcfrAuditorAttestationFlag	true
CY2023	dei	Document Fin Stmt Error Correction Flag DocumentFinStmtErrorCorrectionFlag	false
CY2023	dei	Entity Shell Company EntityShellCompany	false
CY2023Q2	dei	Entity Public Float EntityPublicFloat	153400000	usd
CY2024Q1	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	82529549	shares
CY2023	dei	Auditor Firm AuditorFirmId	1358
CY2023	dei	Auditor Name AuditorName	PricewaterhouseCoopers SA
CY2023	dei	Auditor Location AuditorLocation	Lausanne, Switzerland
CY2023Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	278598000	usd
CY2022Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	326441000	usd
CY2023Q4	us-gaap	Accounts And Other Receivables Net Current AccountsAndOtherReceivablesNetCurrent	25182000	usd
CY2022Q4	us-gaap	Accounts And Other Receivables Net Current AccountsAndOtherReceivablesNetCurrent	72971000	usd
CY2023Q4	us-gaap	Inventory Net InventoryNet	16177000	usd
CY2022Q4	us-gaap	Inventory Net InventoryNet	12073000	usd
CY2023Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	16334000	usd
CY2022Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	23495000	usd
CY2023Q4	us-gaap	Assets Current AssetsCurrent	336291000	usd
CY2022Q4	us-gaap	Assets Current AssetsCurrent	434980000	usd
CY2023Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	5622000	usd
CY2022Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	3355000	usd
CY2023Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	10511000	usd
CY2022Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	6905000	usd
CY2023Q4	us-gaap	Equity Method Investments EquityMethodInvestments	1647000	usd
CY2022Q4	us-gaap	Equity Method Investments EquityMethodInvestments	7613000	usd
CY2023Q4	us-gaap	Deferred Income Tax Assets Net DeferredIncomeTaxAssetsNet	0	usd
CY2022Q4	us-gaap	Deferred Income Tax Assets Net DeferredIncomeTaxAssetsNet	37104000	usd
CY2023Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	711000	usd
CY2022Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	902000	usd
CY2023Q4	us-gaap	Assets Assets	354782000	usd
CY2022Q4	us-gaap	Assets Assets	490859000	usd
CY2023Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	15569000	usd
CY2022Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	12351000	usd
CY2023Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	50634000	usd
CY2022Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	68491000	usd
CY2023Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	1467000	usd
CY2022Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	1097000	usd
CY2023Q4	us-gaap	Liabilities Current LiabilitiesCurrent	67670000	usd
CY2022Q4	us-gaap	Liabilities Current LiabilitiesCurrent	81939000	usd
CY2023Q4	adc	Accrued Royalties Noncurrent AccruedRoyaltiesNoncurrent	303572000	usd
CY2022Q4	adc	Accrued Royalties Noncurrent AccruedRoyaltiesNoncurrent	212353000	usd
CY2023Q4	us-gaap	Secured Long Term Debt SecuredLongTermDebt	112730000	usd
CY2022Q4	us-gaap	Secured Long Term Debt SecuredLongTermDebt	109714000	usd
CY2023Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	10180000	usd
CY2022Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	6564000	usd
CY2023Q4	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	8879000	usd
CY2022Q4	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	838000	usd
CY2023Q4	us-gaap	Liabilities Liabilities	503031000	usd
CY2022Q4	us-gaap	Liabilities Liabilities	411408000	usd
CY2023Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		usd
CY2022Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		usd
CY2023Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.08
CY2022Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.08
CY2023Q4	us-gaap	Common Stock Value CommonStockValue	7312000	usd
CY2022Q4	us-gaap	Common Stock Value CommonStockValue	7312000	usd
CY2023Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	89041946	shares
CY2022Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	89041946	shares
CY2023Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	82293137	shares
CY2022Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	80642527	shares
CY2023Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	1180545000	usd
CY2022Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	1166414000	usd
CY2023Q4	us-gaap	Treasury Stock Value TreasuryStockValue	541000	usd
CY2022Q4	us-gaap	Treasury Stock Value TreasuryStockValue	679000	usd
CY2023Q4	us-gaap	Treasury Stock Common Shares TreasuryStockCommonShares	6748809	shares
CY2022Q4	us-gaap	Treasury Stock Common Shares TreasuryStockCommonShares	8399419	shares
CY2023Q4	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	-93000	usd
CY2022Q4	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	1823000	usd
CY2023Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-1335472000	usd
CY2022Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-1095419000	usd
CY2023Q4	us-gaap	Stockholders Equity StockholdersEquity	-148249000	usd
CY2022Q4	us-gaap	Stockholders Equity StockholdersEquity	79451000	usd
CY2023Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	354782000	usd
CY2022Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	490859000	usd
CY2023	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	69060000	usd
CY2022	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	74908000	usd
CY2023	us-gaap	Revenue Not From Contract With Customer RevenueNotFromContractWithCustomer	498000	usd
CY2022	us-gaap	Revenue Not From Contract With Customer RevenueNotFromContractWithCustomer	135000000	usd
CY2023	us-gaap	Revenues Revenues	69558000	usd
CY2022	us-gaap	Revenues Revenues	209908000	usd
CY2023	us-gaap	Cost Of Revenue CostOfRevenue	2529000	usd
CY2022	us-gaap	Cost Of Revenue CostOfRevenue	3301000	usd
CY2023	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	127127000	usd
CY2022	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	186457000	usd
CY2022	us-gaap	Selling And Marketing Expense SellingAndMarketingExpense	69052000	usd
CY2023	us-gaap	Costs And Expenses CostsAndExpenses	235544000	usd
CY2023	us-gaap	Operating Income Loss OperatingIncomeLoss	-165986000	usd
CY2022	us-gaap	Operating Income Loss OperatingIncomeLoss	-123344000	usd
CY2023	us-gaap	Investment Income Interest InvestmentIncomeInterest	10540000	usd
CY2022	us-gaap	Investment Income Interest InvestmentIncomeInterest	2568000	usd
CY2023	us-gaap	Interest Expense InterestExpense	46325000	usd
CY2022	us-gaap	Interest Expense InterestExpense	36731000	usd
CY2023	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt	0	usd
CY2022	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt	-42114000	usd
CY2023	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	6352000	usd
CY2022	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	52804000	usd
CY2023	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-29433000	usd
CY2022	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-23473000	usd
CY2023	us-gaap	Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments	-195419000	usd
CY2022	us-gaap	Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments	-146817000	usd
CY2023	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	39106000	usd
CY2022	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	227000	usd
CY2023	adc	Income Loss From Continuing Operations Before Equity Method Investments IncomeLossFromContinuingOperationsBeforeEquityMethodInvestments	-234525000	usd
CY2022	adc	Income Loss From Continuing Operations Before Equity Method Investments IncomeLossFromContinuingOperationsBeforeEquityMethodInvestments	-147044000	usd
CY2023	us-gaap	Income Loss From Equity Method Investments IncomeLossFromEquityMethodInvestments	-5528000	usd
CY2022	us-gaap	Income Loss From Equity Method Investments IncomeLossFromEquityMethodInvestments	-10084000	usd
CY2023	us-gaap	Net Income Loss NetIncomeLoss	-240053000	usd
CY2022	us-gaap	Net Income Loss NetIncomeLoss	-157128000	usd
CY2023	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-2.94
CY2023	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-2.94
CY2022	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-2.01
CY2022	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-2.01
CY2023	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	81712166	shares
CY2023	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	81712166	shares
CY2022	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	78152964	shares
CY2022	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	78152964	shares
CY2023	us-gaap	Net Income Loss NetIncomeLoss	-240053000	usd
CY2022	us-gaap	Net Income Loss NetIncomeLoss	-157128000	usd
CY2023	us-gaap	Other Comprehensive Income Defined Benefit Plans Adjustment Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeDefinedBenefitPlansAdjustmentNetOfTaxPortionAttributableToParent	1854000	usd
CY2022	us-gaap	Other Comprehensive Income Defined Benefit Plans Adjustment Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeDefinedBenefitPlansAdjustmentNetOfTaxPortionAttributableToParent	-4116000	usd
CY2023	us-gaap	Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent	376000	usd
CY2022	us-gaap	Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent	-539000	usd
CY2023	adc	Other Comprehensive Income Loss Before Oci Equity Method Investment Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeLossBeforeOCIEquityMethodInvestmentNetOfTaxPortionAttributableToParent	-1478000	usd
CY2022	adc	Other Comprehensive Income Loss Before Oci Equity Method Investment Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeLossBeforeOCIEquityMethodInvestmentNetOfTaxPortionAttributableToParent	3577000	usd
CY2023	us-gaap	Oci Equity Method Investment After Tax Parent OciEquityMethodInvestmentAfterTaxParent	-438000	usd
CY2022	us-gaap	Oci Equity Method Investment After Tax Parent OciEquityMethodInvestmentAfterTaxParent	0	usd
CY2023	us-gaap	Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent	-1916000	usd
CY2022	us-gaap	Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent	3577000	usd
CY2023	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-241969000	usd
CY2022	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-153551000	usd
CY2021Q4	us-gaap	Stockholders Equity StockholdersEquity	154026000	usd
CY2022	us-gaap	Net Income Loss NetIncomeLoss	-157128000	usd
CY2022	us-gaap	Other Comprehensive Income Defined Benefit Plans Adjustment Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeDefinedBenefitPlansAdjustmentNetOfTaxPortionAttributableToParent	-4116000	usd
CY2022	us-gaap	Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent	-539000	usd
CY2022	us-gaap	Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent	3577000	usd
CY2022	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-153551000	usd
CY2022	us-gaap	Stock Issued During Period Value Conversion Of Convertible Securities StockIssuedDuringPeriodValueConversionOfConvertibleSecurities	19834000	usd
CY2022	us-gaap	Stock Issued During Period Value Treasury Stock Reissued StockIssuedDuringPeriodValueTreasuryStockReissued	6130000	usd
CY2022	us-gaap	Stock Issued During Period Value Restricted Stock Award Net Of Forfeitures StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures	0	usd
CY2022	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	49322000	usd
CY2022	us-gaap	Adjustments To Additional Paid In Capital Warrant Issued AdjustmentsToAdditionalPaidInCapitalWarrantIssued	3713000	usd
CY2022	adc	Stockholders Equity Excluding Oci Period Increase Decrease StockholdersEquityExcludingOCIPeriodIncreaseDecrease	78976000	usd
CY2022Q4	us-gaap	Stockholders Equity StockholdersEquity	79451000	usd
CY2023	us-gaap	Net Income Loss NetIncomeLoss	-240053000	usd
CY2023	us-gaap	Other Comprehensive Income Defined Benefit Plans Adjustment Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeDefinedBenefitPlansAdjustmentNetOfTaxPortionAttributableToParent	1854000	usd
CY2023	us-gaap	Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent	376000	usd
CY2023	adc	Other Comprehensive Income Loss Before Oci Equity Method Investment Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeLossBeforeOCIEquityMethodInvestmentNetOfTaxPortionAttributableToParent	-1478000	usd
CY2023	us-gaap	Oci Equity Method Investment After Tax Parent OciEquityMethodInvestmentAfterTaxParent	-438000	usd
CY2023	us-gaap	Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent	-1916000	usd
CY2023	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-241969000	usd
CY2023	us-gaap	Stock Issued During Period Value Restricted Stock Award Net Of Forfeitures StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures	0	usd
CY2023	us-gaap	Stock Issued During Period Value Employee Stock Purchase Plan StockIssuedDuringPeriodValueEmployeeStockPurchasePlan	774000	usd
CY2023	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	13495000	usd
CY2023	adc	Stockholders Equity Excluding Oci Period Increase Decrease StockholdersEquityExcludingOCIPeriodIncreaseDecrease	14269000	usd
CY2023Q4	us-gaap	Stockholders Equity StockholdersEquity	-148249000	usd
CY2023	us-gaap	Net Income Loss NetIncomeLoss	-240053000	usd
CY2022	us-gaap	Net Income Loss NetIncomeLoss	-157128000	usd
CY2023	us-gaap	Deferred Income Taxes And Tax Credits DeferredIncomeTaxesAndTaxCredits	37104000	usd
CY2022	us-gaap	Deferred Income Taxes And Tax Credits DeferredIncomeTaxesAndTaxCredits	-1621000	usd
CY2023	us-gaap	Share Based Compensation ShareBasedCompensation	13495000	usd
CY2022	us-gaap	Share Based Compensation ShareBasedCompensation	49322000	usd
CY2023	us-gaap	Amortization Of Advance Royalty AmortizationOfAdvanceRoyalty	19207000	usd
CY2022	us-gaap	Amortization Of Advance Royalty AmortizationOfAdvanceRoyalty	12202000	usd
CY2023	adc	Deferred Royalty Obligation Cumulative Catch Up Adjustment DeferredRoyaltyObligationCumulativeCatchUpAdjustment	-4972000	usd
CY2022	adc	Deferred Royalty Obligation Cumulative Catch Up Adjustment DeferredRoyaltyObligationCumulativeCatchUpAdjustment	-15402000	usd
CY2023	us-gaap	Inventory Write Down InventoryWriteDown	1608000	usd
CY2022	us-gaap	Inventory Write Down InventoryWriteDown	2165000	usd
CY2023	us-gaap	Depreciation Depreciation	1187000	usd
CY2022	us-gaap	Depreciation Depreciation	1060000	usd
CY2023	us-gaap	Operating Lease Right Of Use Asset Amortization Expense OperatingLeaseRightOfUseAssetAmortizationExpense	2080000	usd
CY2022	us-gaap	Operating Lease Right Of Use Asset Amortization Expense OperatingLeaseRightOfUseAssetAmortizationExpense	1328000	usd
CY2023	us-gaap	Income Loss From Equity Method Investments IncomeLossFromEquityMethodInvestments	-5528000	usd
CY2022	us-gaap	Income Loss From Equity Method Investments IncomeLossFromEquityMethodInvestments	-10084000	usd
CY2023	us-gaap	Unrealized Gain Loss On Derivatives UnrealizedGainLossOnDerivatives	0	usd
CY2022	us-gaap	Unrealized Gain Loss On Derivatives UnrealizedGainLossOnDerivatives	25650000	usd
CY2023	us-gaap	Pension Expense Reversal Of Expense Noncash PensionExpenseReversalOfExpenseNoncash	-712000	usd
CY2022	us-gaap	Pension Expense Reversal Of Expense Noncash PensionExpenseReversalOfExpenseNoncash	0	usd
CY2023	us-gaap	Fair Value Adjustment Of Warrants FairValueAdjustmentOfWarrants	-497000	usd
CY2022	us-gaap	Fair Value Adjustment Of Warrants FairValueAdjustmentOfWarrants	-11504000	usd
CY2023	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt	0	usd
CY2022	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt	-42114000	usd
CY2023	us-gaap	Other Noncash Income Expense OtherNoncashIncomeExpense	-52000	usd
CY2022	us-gaap	Other Noncash Income Expense OtherNoncashIncomeExpense	-91000	usd
CY2023	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	-47789000	usd
CY2022	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	42753000	usd
CY2023	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	5712000	usd
CY2022	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	9651000	usd
CY2023	us-gaap	Increase Decrease In Other Current Assets IncreaseDecreaseInOtherCurrentAssets	-7289000	usd
CY2022	us-gaap	Increase Decrease In Other Current Assets IncreaseDecreaseInOtherCurrentAssets	11464000	usd
CY2023	us-gaap	Increase Decrease In Other Noncurrent Assets IncreaseDecreaseInOtherNoncurrentAssets	-200000	usd
CY2022	us-gaap	Increase Decrease In Other Noncurrent Assets IncreaseDecreaseInOtherNoncurrentAssets	210000	usd
CY2023	us-gaap	Increase Decrease In Accounts Payable Trade IncreaseDecreaseInAccountsPayableTrade	3173000	usd
CY2022	us-gaap	Increase Decrease In Accounts Payable Trade IncreaseDecreaseInAccountsPayableTrade	310000	usd
CY2023	us-gaap	Increase Decrease In Accrued Liabilities IncreaseDecreaseInAccruedLiabilities	-14143000	usd
CY2022	us-gaap	Increase Decrease In Accrued Liabilities IncreaseDecreaseInAccruedLiabilities	16246000	usd
CY2023	us-gaap	Increase Decrease In Operating Lease Liability IncreaseDecreaseInOperatingLeaseLiability	-1716000	usd
CY2022	us-gaap	Increase Decrease In Operating Lease Liability IncreaseDecreaseInOperatingLeaseLiability	-1203000	usd
CY2023	us-gaap	Increase Decrease In Other Noncurrent Liabilities IncreaseDecreaseInOtherNoncurrentLiabilities	7391000	usd
CY2022	us-gaap	Increase Decrease In Other Noncurrent Liabilities IncreaseDecreaseInOtherNoncurrentLiabilities	0	usd
CY2023	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-118686000	usd
CY2022	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-138311000	usd
CY2023	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	3216000	usd
CY2022	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	687000	usd
CY2023	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-3216000	usd
CY2022	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-687000	usd
CY2023	adc	Proceeds From Royalties Received Net Of Transaction Costs ProceedsFromRoyaltiesReceivedNetOfTransactionCosts	73102000	usd
CY2022	adc	Proceeds From Royalties Received Net Of Transaction Costs ProceedsFromRoyaltiesReceivedNetOfTransactionCosts	0	usd
CY2023	us-gaap	Proceeds From Stock Plans ProceedsFromStockPlans	773000	usd
CY2022	us-gaap	Proceeds From Stock Plans ProceedsFromStockPlans	0	usd
CY2023	us-gaap	Proceeds From Issuance Of Secured Debt ProceedsFromIssuanceOfSecuredDebt	0	usd
CY2022	us-gaap	Proceeds From Issuance Of Secured Debt ProceedsFromIssuanceOfSecuredDebt	115597000	usd
CY2023	us-gaap	Payments Of Debt Issuance Costs PaymentsOfDebtIssuanceCosts	0	usd
CY2022	us-gaap	Payments Of Debt Issuance Costs PaymentsOfDebtIssuanceCosts	2784000	usd
CY2023	us-gaap	Repayments Of Convertible Debt RepaymentsOfConvertibleDebt	0	usd
CY2022	us-gaap	Repayments Of Convertible Debt RepaymentsOfConvertibleDebt	118304000	usd
CY2023	us-gaap	Proceeds From Sale Of Treasury Stock ProceedsFromSaleOfTreasuryStock	0	usd
CY2022	us-gaap	Proceeds From Sale Of Treasury Stock ProceedsFromSaleOfTreasuryStock	6130000	usd
CY2023	us-gaap	Payments Of Stock Issuance Costs PaymentsOfStockIssuanceCosts	0	usd
CY2022	us-gaap	Payments Of Stock Issuance Costs PaymentsOfStockIssuanceCosts	221000	usd
CY2023	us-gaap	Payments Related To Tax Withholding For Share Based Compensation PaymentsRelatedToTaxWithholdingForShareBasedCompensation	0	usd
CY2022	us-gaap	Payments Related To Tax Withholding For Share Based Compensation PaymentsRelatedToTaxWithholdingForShareBasedCompensation	1315000	usd
CY2023	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	73875000	usd
CY2022	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	-897000	usd
CY2023	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect	-48027000	usd
CY2022	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect	-139895000	usd
CY2023	us-gaap	Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	184000	usd
CY2022	us-gaap	Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	-208000	usd
CY2022Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	326441000	usd
CY2021Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	466544000	usd
CY2023Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	278598000	usd
CY2022Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	326441000	usd
CY2023	us-gaap	Interest Paid Net InterestPaidNet	15387000	usd
CY2022	us-gaap	Interest Paid Net InterestPaidNet	10178000	usd
CY2023	us-gaap	Proceeds From Interest Received ProceedsFromInterestReceived	9725000	usd
CY2022	us-gaap	Proceeds From Interest Received ProceedsFromInterestReceived	1948000	usd
CY2023	adc	Noncash Payment For Royalty Financing Transaction NoncashPaymentForRoyaltyFinancingTransaction	-8709000	usd
CY2022	adc	Noncash Payment For Royalty Financing Transaction NoncashPaymentForRoyaltyFinancingTransaction	-10998000	usd
CY2023	us-gaap	Stock Issued1 StockIssued1	0	usd
CY2022	us-gaap	Stock Issued1 StockIssued1	19834000	usd
CY2023	us-gaap	Capital Expenditures Incurred But Not Yet Paid CapitalExpendituresIncurredButNotYetPaid	65000	usd
CY2022	us-gaap	Capital Expenditures Incurred But Not Yet Paid CapitalExpendituresIncurredButNotYetPaid	0	usd
CY2023	adc	Number Of Subsidiaries NumberOfSubsidiaries	3	subsidiary
CY2023	us-gaap	Use Of Estimates UseOfEstimates	<div style="padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:112%">Use of Estimates</span></div><div style="padding-left:18pt"><span><br/></span></div><div style="padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets, liabilities, revenues and expenses, and related disclosures in the consolidated financial statements and accompanying notes. Management bases its estimates on historical experience and on assumptions believed to be reasonable under the circumstances. Actual results could differ materially from those estimates.</span></div>
CY2023Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	278600000	usd
CY2022Q4	adc	Accounts Receivable License Fees AccountsReceivableLicenseFees	50000000	usd
CY2023	us-gaap	Number Of Operating Segments NumberOfOperatingSegments	1	segment
CY2023Q4	adc	Assets Noncurrent Excluding Joint Ventures AssetsNoncurrentExcludingJointVentures	16844000	usd
CY2022Q4	adc	Assets Noncurrent Excluding Joint Ventures AssetsNoncurrentExcludingJointVentures	11162000	usd
CY2023Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	5622000	usd
CY2022Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	3355000	usd
CY2023	us-gaap	Depreciation Depreciation	1187000	usd
CY2022	us-gaap	Depreciation Depreciation	1060000	usd
CY2023Q4	us-gaap	Warrants And Rights Outstanding WarrantsAndRightsOutstanding	296000	usd
CY2023Q4	us-gaap	Liabilities Fair Value Disclosure LiabilitiesFairValueDisclosure	296000	usd
CY2022Q4	us-gaap	Warrants And Rights Outstanding WarrantsAndRightsOutstanding	793000	usd
CY2022Q4	us-gaap	Liabilities Fair Value Disclosure LiabilitiesFairValueDisclosure	793000	usd
CY2023Q4	us-gaap	Inventory Work In Process Net Of Reserves InventoryWorkInProcessNetOfReserves	16095000	usd
CY2022Q4	us-gaap	Inventory Work In Process Net Of Reserves InventoryWorkInProcessNetOfReserves	12057000	usd
CY2023Q4	us-gaap	Inventory Finished Goods Net Of Reserves InventoryFinishedGoodsNetOfReserves	82000	usd
CY2022Q4	us-gaap	Inventory Finished Goods Net Of Reserves InventoryFinishedGoodsNetOfReserves	16000	usd
CY2023Q4	us-gaap	Inventory Net InventoryNet	16177000	usd
CY2022Q4	us-gaap	Inventory Net InventoryNet	12073000	usd
CY2023	us-gaap	Inventory Write Down InventoryWriteDown	1608000	usd
CY2022	us-gaap	Inventory Write Down InventoryWriteDown	2165000	usd
CY2023Q4	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	9897000	usd
CY2022Q4	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	6763000	usd
CY2023Q4	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	4275000	usd
CY2022Q4	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	3408000	usd
CY2023	us-gaap	Right Of Use Asset Obtained In Exchange For Operating Lease Liability RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability	4900000	usd
CY2022	us-gaap	Right Of Use Asset Obtained In Exchange For Operating Lease Liability RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability	1200000	usd
CY2023	us-gaap	Operating Lease Cost OperatingLeaseCost	2080000	usd
CY2022	us-gaap	Operating Lease Cost OperatingLeaseCost	1328000	usd
CY2023Q4	us-gaap	Short Term Lease Commitment Amount ShortTermLeaseCommitmentAmount	3000	usd
CY2023Q4	us-gaap	Lessee Operating Lease Liability Payments Due Next Twelve Months LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths	1955000	usd
CY2023Q4	us-gaap	Lessee Operating Lease Liability Payments Due Year Two LesseeOperatingLeaseLiabilityPaymentsDueYearTwo	1939000	usd
CY2023Q4	us-gaap	Lessee Operating Lease Liability Payments Due Year Three LesseeOperatingLeaseLiabilityPaymentsDueYearThree	1976000	usd
CY2023Q4	us-gaap	Lessee Operating Lease Liability Payments Due Year Four LesseeOperatingLeaseLiabilityPaymentsDueYearFour	1991000	usd
CY2023Q4	us-gaap	Lessee Operating Lease Liability Payments Due Year Five LesseeOperatingLeaseLiabilityPaymentsDueYearFive	1794000	usd
CY2023Q4	us-gaap	Lessee Operating Lease Liability Payments Due After Year Five LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive	3999000	usd
CY2023Q4	us-gaap	Lessee Operating Lease Liability Payments Due LesseeOperatingLeaseLiabilityPaymentsDue	13654000	usd
CY2023Q4	us-gaap	Lessee Operating Lease Liability Undiscounted Excess Amount LesseeOperatingLeaseLiabilityUndiscountedExcessAmount	2007000	usd
CY2023Q4	us-gaap	Operating Lease Liability OperatingLeaseLiability	11647000	usd
CY2023Q4	us-gaap	Operating Lease Weighted Average Remaining Lease Term1 OperatingLeaseWeightedAverageRemainingLeaseTerm1	P7Y1M6D
CY2022Q4	us-gaap	Operating Lease Weighted Average Remaining Lease Term1 OperatingLeaseWeightedAverageRemainingLeaseTerm1	P6Y10M24D
CY2023Q4	us-gaap	Operating Lease Weighted Average Discount Rate Percent OperatingLeaseWeightedAverageDiscountRatePercent	0.044
CY2022Q4	us-gaap	Operating Lease Weighted Average Discount Rate Percent OperatingLeaseWeightedAverageDiscountRatePercent	0.026
CY2023	us-gaap	Income Loss From Continuing Operations Before Income Taxes Domestic IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic	-7888000	usd
CY2022	us-gaap	Income Loss From Continuing Operations Before Income Taxes Domestic IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic	12206000	usd
CY2023	us-gaap	Income Loss From Continuing Operations Before Income Taxes Foreign IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign	-187531000	usd
CY2022	us-gaap	Income Loss From Continuing Operations Before Income Taxes Foreign IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign	-159023000	usd
CY2023	us-gaap	Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments	-195419000	usd
CY2022	us-gaap	Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments	-146817000	usd
CY2023	us-gaap	Current Federal State And Local Tax Expense Benefit CurrentFederalStateAndLocalTaxExpenseBenefit	1479000	usd
CY2023	us-gaap	Deferred Federal State And Local Tax Expense Benefit DeferredFederalStateAndLocalTaxExpenseBenefit	37104000	usd
CY2023	us-gaap	Current Foreign Tax Expense Benefit CurrentForeignTaxExpenseBenefit	523000	usd
CY2023	us-gaap	Deferred Foreign Income Tax Expense Benefit DeferredForeignIncomeTaxExpenseBenefit	0	usd
CY2023	us-gaap	Current Income Tax Expense Benefit CurrentIncomeTaxExpenseBenefit	2002000	usd
CY2023	us-gaap	Deferred Income Tax Expense Benefit DeferredIncomeTaxExpenseBenefit	37104000	usd
CY2022	us-gaap	Current Federal State And Local Tax Expense Benefit CurrentFederalStateAndLocalTaxExpenseBenefit	1737000	usd
CY2022	us-gaap	Deferred Federal State And Local Tax Expense Benefit DeferredFederalStateAndLocalTaxExpenseBenefit	-1621000	usd
CY2022	us-gaap	Current Foreign Tax Expense Benefit CurrentForeignTaxExpenseBenefit	111000	usd
CY2022	us-gaap	Deferred Foreign Income Tax Expense Benefit DeferredForeignIncomeTaxExpenseBenefit	0	usd
CY2022	us-gaap	Current Income Tax Expense Benefit CurrentIncomeTaxExpenseBenefit	1848000	usd
CY2022	us-gaap	Deferred Income Tax Expense Benefit DeferredIncomeTaxExpenseBenefit	-1621000	usd
CY2023	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	39106000	usd
CY2022	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	227000	usd
CY2023	us-gaap	Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments	-195419000	usd
CY2022	us-gaap	Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments	-146817000	usd
CY2023	us-gaap	Income Tax Reconciliation Income Tax Expense Benefit At Federal Statutory Income Tax Rate IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate	-26694000	usd
CY2022	us-gaap	Income Tax Reconciliation Income Tax Expense Benefit At Federal Statutory Income Tax Rate IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate	-20041000	usd
CY2023	us-gaap	Income Tax Reconciliation Foreign Income Tax Rate Differential IncomeTaxReconciliationForeignIncomeTaxRateDifferential	-343000	usd
CY2022	us-gaap	Income Tax Reconciliation Foreign Income Tax Rate Differential IncomeTaxReconciliationForeignIncomeTaxRateDifferential	982000	usd
CY2023	us-gaap	Income Tax Reconciliation State And Local Income Taxes IncomeTaxReconciliationStateAndLocalIncomeTaxes	-1022000	usd
CY2022	us-gaap	Income Tax Reconciliation State And Local Income Taxes IncomeTaxReconciliationStateAndLocalIncomeTaxes	-654000	usd
CY2023	us-gaap	Income Tax Reconciliation Tax Credits Research IncomeTaxReconciliationTaxCreditsResearch	5800000	usd
CY2022	us-gaap	Income Tax Reconciliation Tax Credits Research IncomeTaxReconciliationTaxCreditsResearch	6110000	usd
CY2023	us-gaap	Income Tax Reconciliation Nondeductible Expense Share Based Compensation Cost IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost	2858000	usd
CY2022	us-gaap	Income Tax Reconciliation Nondeductible Expense Share Based Compensation Cost IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost	5143000	usd
CY2023	adc	Effective Income Tax Rate Reconciliation Return To Provision Amount EffectiveIncomeTaxRateReconciliationReturnToProvisionAmount	-4745000	usd
CY2022	adc	Effective Income Tax Rate Reconciliation Return To Provision Amount EffectiveIncomeTaxRateReconciliationReturnToProvisionAmount	629000	usd
CY2023	us-gaap	Income Tax Reconciliation Nondeductible Expense IncomeTaxReconciliationNondeductibleExpense	1576000	usd
CY2022	us-gaap	Income Tax Reconciliation Nondeductible Expense IncomeTaxReconciliationNondeductibleExpense	6585000	usd
CY2023	us-gaap	Income Tax Reconciliation Change In Deferred Tax Assets Valuation Allowance IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance	66989000	usd
CY2022	us-gaap	Income Tax Reconciliation Change In Deferred Tax Assets Valuation Allowance IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance	9435000	usd
CY2023	us-gaap	Income Tax Reconciliation Other Reconciling Items IncomeTaxReconciliationOtherReconcilingItems	6287000	usd
CY2022	us-gaap	Income Tax Reconciliation Other Reconciling Items IncomeTaxReconciliationOtherReconcilingItems	4258000	usd
CY2023	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	39106000	usd
CY2022	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	227000	usd
CY2023Q4	us-gaap	Deferred Tax Assets Operating Loss Carryforwards DeferredTaxAssetsOperatingLossCarryforwards	162877000	usd
CY2022Q4	us-gaap	Deferred Tax Assets Operating Loss Carryforwards DeferredTaxAssetsOperatingLossCarryforwards	131120000	usd
CY2023Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost	14873000	usd
CY2022Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost	15645000	usd
CY2023Q4	us-gaap	Deferred Tax Assets In Process Research And Development DeferredTaxAssetsInProcessResearchAndDevelopment	2546000	usd
CY2022Q4	us-gaap	Deferred Tax Assets In Process Research And Development DeferredTaxAssetsInProcessResearchAndDevelopment	0	usd
CY2023Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Reserves And Accruals Reserves DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsReserves	1843000	usd
CY2022Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Reserves And Accruals Reserves DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsReserves	0	usd
CY2023Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Reserves And Accruals Other DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsOther	3326000	usd
CY2022Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Reserves And Accruals Other DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsOther	3672000	usd
CY2023Q4	us-gaap	Deferred Tax Assets Gross DeferredTaxAssetsGross	213488000	usd
CY2022Q4	us-gaap	Deferred Tax Assets Gross DeferredTaxAssetsGross	172295000	usd
CY2023Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	212156000	usd
CY2022Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	131197000	usd
CY2023Q4	us-gaap	Deferred Tax Assets Net DeferredTaxAssetsNet	1332000	usd
CY2022Q4	us-gaap	Deferred Tax Assets Net DeferredTaxAssetsNet	41098000	usd
CY2023Q4	us-gaap	Deferred Tax Liabilities Investments DeferredTaxLiabilitiesInvestments	225000	usd
CY2022Q4	us-gaap	Deferred Tax Liabilities Investments DeferredTaxLiabilitiesInvestments	1039000	usd
CY2023Q4	us-gaap	Deferred Tax Liabilities Other DeferredTaxLiabilitiesOther	1107000	usd
CY2022Q4	us-gaap	Deferred Tax Liabilities Other DeferredTaxLiabilitiesOther	2955000	usd
CY2022Q4	adc	Accrued Expenses And Other Current Liabilities AccruedExpensesAndOtherCurrentLiabilities	68491000	usd
CY2022Q3	us-gaap	Stock Issued During Period Shares Treasury Stock Reissued StockIssuedDuringPeriodSharesTreasuryStockReissued	733568	shares
CY2022Q3	us-gaap	Proceeds From Convertible Debt ProceedsFromConvertibleDebt	6250000	usd
CY2022Q3	us-gaap	Proceeds From Issuance Of Warrants ProceedsFromIssuanceOfWarrants	0	usd
CY2023Q4	us-gaap	Deferred Income Tax Liabilities DeferredIncomeTaxLiabilities	1332000	usd
CY2022Q4	us-gaap	Deferred Income Tax Liabilities DeferredIncomeTaxLiabilities	3994000	usd
CY2023Q4	us-gaap	Deferred Income Tax Liabilities Net DeferredIncomeTaxLiabilitiesNet	1332000	usd
CY2022Q4	us-gaap	Deferred Income Tax Liabilities Net DeferredIncomeTaxLiabilitiesNet	3994000	usd
CY2023Q4	us-gaap	Deferred Tax Assets Liabilities Net DeferredTaxAssetsLiabilitiesNet	0	usd
CY2022Q4	us-gaap	Deferred Tax Assets Liabilities Net DeferredTaxAssetsLiabilitiesNet	37104000	usd
CY2023	us-gaap	Valuation Allowance Deferred Tax Asset Change In Amount ValuationAllowanceDeferredTaxAssetChangeInAmount	81000000.0	usd
CY2022	us-gaap	Valuation Allowance Deferred Tax Asset Change In Amount ValuationAllowanceDeferredTaxAssetChangeInAmount	8600000	usd
CY2023Q4	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	6600000	usd
CY2022Q4	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	5200000	usd
CY2022Q4	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	5184000	usd
CY2021Q4	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	4425000	usd
CY2023	us-gaap	Unrecognized Tax Benefits Increases Resulting From Current Period Tax Positions UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions	1463000	usd
CY2022	us-gaap	Unrecognized Tax Benefits Increases Resulting From Current Period Tax Positions UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions	783000	usd
CY2023	us-gaap	Unrecognized Tax Benefits Reductions Resulting From Lapse Of Applicable Statute Of Limitations UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations	30000	usd
CY2022	us-gaap	Unrecognized Tax Benefits Reductions Resulting From Lapse Of Applicable Statute Of Limitations UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations	24000	usd
CY2023Q4	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	6617000	usd
CY2022Q4	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	5184000	usd
CY2023Q4	adc	Accrued Research And Development Costs Current AccruedResearchAndDevelopmentCostsCurrent	24902000	usd
CY2022Q4	adc	Accrued Research And Development Costs Current AccruedResearchAndDevelopmentCostsCurrent	35627000	usd
CY2023Q4	us-gaap	Accrued Employee Benefits Current AccruedEmployeeBenefitsCurrent	12693000	usd
CY2022Q4	us-gaap	Accrued Employee Benefits Current AccruedEmployeeBenefitsCurrent	16306000	usd
CY2023Q4	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	13039000	usd
CY2022Q4	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	16558000	usd
CY2023Q4	adc	Accrued Expenses And Other Current Liabilities AccruedExpensesAndOtherCurrentLiabilities	50634000	usd
CY2022Q3	adc	Proceeds Received For Issuance Of Common Stock Warrants And Long Term Debt ProceedsReceivedForIssuanceOfCommonStockWarrantsAndLongTermDebt	126250000	usd
CY2022Q3	adc	Stock Issued During Period Value Treasury Stock Reissued Gross StockIssuedDuringPeriodValueTreasuryStockReissuedGross	6250000	usd
CY2022Q3	us-gaap	Warrants And Rights Outstanding WarrantsAndRightsOutstanding	3957000	usd
CY2022Q3	adc	Allocation Of Proceeds Received For Issuance Of Common Stock Warrants And Long Term Debt AllocationOfProceedsReceivedForIssuanceOfCommonStockWarrantsAndLongTermDebt	126250000	usd
CY2022Q3	adc	Stock Issued During Period Value Treasury Stock Reissued Gross StockIssuedDuringPeriodValueTreasuryStockReissuedGross	6250000	usd
CY2022Q3	us-gaap	Warrants And Rights Outstanding WarrantsAndRightsOutstanding	3957000	usd
CY2022Q3	adc	Allocation Of Proceeds Received For Issuance Of Common Stock Warrants And Long Term Debt AllocationOfProceedsReceivedForIssuanceOfCommonStockWarrantsAndLongTermDebt	126250000	usd
CY2022Q3	us-gaap	Payments Of Stock Issuance Costs PaymentsOfStockIssuanceCosts	120000	usd
CY2022Q3	adc	Payment Of Warrant Issuance Costs PaymentOfWarrantIssuanceCosts	244000	usd
CY2022Q3	us-gaap	Payments Of Financing Costs PaymentsOfFinancingCosts	7551000	usd
CY2023Q4	us-gaap	Secured Long Term Debt SecuredLongTermDebt	112700000	usd
CY2022Q4	us-gaap	Secured Long Term Debt SecuredLongTermDebt	109700000	usd
CY2022	us-gaap	Embedded Derivative Gain Loss On Embedded Derivative Net EmbeddedDerivativeGainLossOnEmbeddedDerivativeNet	25650000	usd
CY2022Q4	us-gaap	Embedded Derivative Fair Value Of Embedded Derivative Liability EmbeddedDerivativeFairValueOfEmbeddedDerivativeLiability	0	usd
CY2021Q3	adc	Royalty Purchase Agreement RoyaltyPurchaseAgreement	325000000	usd
CY2021Q3	us-gaap	Proceeds From Royalties Received ProceedsFromRoyaltiesReceived	225000000	usd
CY2023	us-gaap	Proceeds From Royalties Received ProceedsFromRoyaltiesReceived	75000000	usd
CY2021Q3	adc	Royalty Purchase Agreement Percent Of Milestone Payments RoyaltyPurchaseAgreementPercentOfMilestonePayments	0.07
CY2021Q3	adc	Royalty Purchase Agreement Percent Of Performance Tests RoyaltyPurchaseAgreementPercentOfPerformanceTests	0.10
CY2021Q3	adc	Royalty Purchase Agreement Percent Sales RoyaltyPurchaseAgreementPercentSales	0.07
CY2021Q3	adc	Royalty Purchase Agreement High Single Digit Percentage Rate RoyaltyPurchaseAgreementHighSingleDigitPercentageRate	0.10
CY2021Q3	adc	Royalty Purchase Agreement Royalty Cap Period Of Payment RoyaltyPurchaseAgreementRoyaltyCapPeriodOfPayment	P36M
CY2021Q3	adc	Royalty Purchase Agreement Royalty Cap Payment Percent RoyaltyPurchaseAgreementRoyaltyCapPaymentPercent	2.0
CY2021Q3	adc	Royalty Purchase Agreement Royalty Cap Termination Period RoyaltyPurchaseAgreementRoyaltyCapTerminationPeriod	P27M
CY2021Q3	adc	Royalty Purchase Agreement Buyout Percent Of Investment RoyaltyPurchaseAgreementBuyoutPercentOfInvestment	0.50
CY2021Q3	adc	Royalty Purchase Agreement Buyout Percent Of Payments RoyaltyPurchaseAgreementBuyoutPercentOfPayments	0.50
CY2021Q3	adc	Royalty Purchase Agreement Buyout Percent Of Investment RoyaltyPurchaseAgreementBuyoutPercentOfInvestment	0.50
CY2021	us-gaap	Proceeds From Royalties Received ProceedsFromRoyaltiesReceived	225000000	usd
CY2021	adc	Royalty Obligation Transaction Costs RoyaltyObligationTransactionCosts	7000000	usd
CY2021	adc	Proceeds From Royalties Net Of Transaction Costs ProceedsFromRoyaltiesNetOfTransactionCosts	218000000	usd
CY2023	us-gaap	Proceeds From Royalties Received ProceedsFromRoyaltiesReceived	75000000	usd
CY2023	adc	Proceeds From Royalties Net Of Transaction Costs ProceedsFromRoyaltiesNetOfTransactionCosts	73100000	usd
CY2023	adc	Royalty Obligation Transaction Costs RoyaltyObligationTransactionCosts	1900000	usd
CY2021Q4	adc	Deferred Royalty Obligation DeferredRoyaltyObligation	225477000	usd
CY2022	adc	Increase Decrease To Royalty Obligation Royalty Payments IncreaseDecreaseToRoyaltyObligationRoyaltyPayments	-10998000	usd
CY2022	adc	Increase Decrease To Royalty Obligation Interest Expense IncreaseDecreaseToRoyaltyObligationInterestExpense	23200000	usd
CY2022	adc	Increase Decrease To Royalty Obligation Cumulative Catch Up Adjustment Other Net IncreaseDecreaseToRoyaltyObligationCumulativeCatchUpAdjustmentOtherNet	-15402000	usd
CY2022Q4	adc	Deferred Royalty Obligation DeferredRoyaltyObligation	222277000	usd
CY2023	adc	Increase Decrease To Royalty Obligation Additional Proceeds From Sale Of Future Royalties IncreaseDecreaseToRoyaltyObligationAdditionalProceedsFromSaleOfFutureRoyalties	75000000	usd
CY2023	adc	Increase Decrease To Royalty Obligation Transaction Costs IncreaseDecreaseToRoyaltyObligationTransactionCosts	-1898000	usd
CY2023	adc	Increase Decrease To Royalty Obligation Royalty Payments IncreaseDecreaseToRoyaltyObligationRoyaltyPayments	-8709000	usd
CY2023	adc	Increase Decrease To Royalty Obligation Interest Expense IncreaseDecreaseToRoyaltyObligationInterestExpense	27915000	usd
CY2023	adc	Increase Decrease To Royalty Obligation Cumulative Catch Up Adjustment Other Net IncreaseDecreaseToRoyaltyObligationCumulativeCatchUpAdjustmentOtherNet	-4972000	usd
CY2023Q4	adc	Deferred Royalty Obligation DeferredRoyaltyObligation	309613000	usd
CY2021Q3	adc	Royalty Obligation Effective Interest Rate RoyaltyObligationEffectiveInterestRate	0.10
CY2023	adc	Increase Decrease To Royalty Obligation Royalty Payments IncreaseDecreaseToRoyaltyObligationRoyaltyPayments	-8709000	usd
CY2022	adc	Increase Decrease To Royalty Obligation Royalty Payments IncreaseDecreaseToRoyaltyObligationRoyaltyPayments	-10998000	usd
CY2023	adc	Deferred Royalty Obligation Cumulative Catch Up Adjustment DeferredRoyaltyObligationCumulativeCatchUpAdjustment	-4972000	usd
CY2022	adc	Deferred Royalty Obligation Cumulative Catch Up Adjustment DeferredRoyaltyObligationCumulativeCatchUpAdjustment	-15402000	usd
CY2021Q3	adc	Royalty Obligation Effective Interest Rate RoyaltyObligationEffectiveInterestRate	0.10
CY2023	adc	Capital And Interest Guarantee Defined Benefit Plan CapitalAndInterestGuaranteeDefinedBenefitPlan	1
CY2023	adc	Defined Benefit Plan Guaranteed Interest Return On Employees Savings Employee Savings DefinedBenefitPlanGuaranteedInterestReturnOnEmployeesSavingsEmployeeSavings	0.01
CY2023	adc	Defined Benefit Plan Guaranteed Interest Return On Employees Savings Supplementary Retirement Savings DefinedBenefitPlanGuaranteedInterestReturnOnEmployeesSavingsSupplementaryRetirementSavings	0.0025
CY2023	adc	Defined Benefit Plans Retirement Age Males DefinedBenefitPlansRetirementAgeMales	65	age
CY2023	adc	Defined Benefit Plan Retirement Age Females DefinedBenefitPlanRetirementAgeFemales	64	age
CY2023	adc	Defined Benefit Plan Rate To Convert Mandatory Savings To Annuity For Females DefinedBenefitPlanRateToConvertMandatorySavingsToAnnuityForFemales	0.0568
CY2023	adc	Defined Benefit Plan Rate To Convert Supplementary Savings To Annuity For Males DefinedBenefitPlanRateToConvertSupplementarySavingsToAnnuityForMales	0.044855
CY2023	adc	Defined Benefit Plan Rate To Convert Supplementary Savings To Annuity For Males DefinedBenefitPlanRateToConvertSupplementarySavingsToAnnuityForMales	0.044855
CY2023	adc	Defined Benefit Plan Rate To Convert Supplementary Savings To Annuity For Females DefinedBenefitPlanRateToConvertSupplementarySavingsToAnnuityForFemales	0.045411
CY2023	adc	Defined Benefit Plan Rate To Convert Supplementary Savings To Annuity For Females DefinedBenefitPlanRateToConvertSupplementarySavingsToAnnuityForFemales	0.045411
CY2022Q4	us-gaap	Defined Benefit Plan Benefit Obligation DefinedBenefitPlanBenefitObligation	12685000	usd
CY2021Q4	us-gaap	Defined Benefit Plan Benefit Obligation DefinedBenefitPlanBenefitObligation	15279000	usd
CY2023	us-gaap	Defined Benefit Plan Service Cost DefinedBenefitPlanServiceCost	736000	usd
CY2022	us-gaap	Defined Benefit Plan Service Cost DefinedBenefitPlanServiceCost	1234000	usd
CY2023	us-gaap	Defined Benefit Plan Interest Cost DefinedBenefitPlanInterestCost	254000	usd
CY2022	us-gaap	Defined Benefit Plan Interest Cost DefinedBenefitPlanInterestCost	53000	usd
CY2023	us-gaap	Defined Benefit Plan Actuarial Gain Loss DefinedBenefitPlanActuarialGainLoss	-1445000	usd
CY2022	us-gaap	Defined Benefit Plan Actuarial Gain Loss DefinedBenefitPlanActuarialGainLoss	3947000	usd
CY2023	adc	Defined Benefit Plan Benefit Obligation Benefits Paid Credited DefinedBenefitPlanBenefitObligationBenefitsPaidCredited	99000	usd
CY2022	adc	Defined Benefit Plan Benefit Obligation Benefits Paid Credited DefinedBenefitPlanBenefitObligationBenefitsPaidCredited	-7000	usd
CY2023	adc	Defined Benefit Plan Benefit Obligation Contributions By Employer DefinedBenefitPlanBenefitObligationContributionsByEmployer	421000	usd
CY2022	adc	Defined Benefit Plan Benefit Obligation Contributions By Employer DefinedBenefitPlanBenefitObligationContributionsByEmployer	466000	usd
CY2023	adc	Defined Benefit Plan Benefit Obligation Increase Decrease For Settlement And Curtailment DefinedBenefitPlanBenefitObligationIncreaseDecreaseForSettlementAndCurtailment	5482000	usd
CY2022	adc	Defined Benefit Plan Benefit Obligation Increase Decrease For Settlement And Curtailment DefinedBenefitPlanBenefitObligationIncreaseDecreaseForSettlementAndCurtailment	0	usd
CY2023	us-gaap	Defined Benefit Plan Plan Amendments DefinedBenefitPlanPlanAmendments	-33000	usd
CY2022	us-gaap	Defined Benefit Plan Plan Amendments DefinedBenefitPlanPlanAmendments	-179000	usd
CY2023	us-gaap	Defined Benefit Plan Foreign Currency Exchange Rate Changes Benefit Obligation DefinedBenefitPlanForeignCurrencyExchangeRateChangesBenefitObligation	-1174000	usd
CY2022	us-gaap	Defined Benefit Plan Foreign Currency Exchange Rate Changes Benefit Obligation DefinedBenefitPlanForeignCurrencyExchangeRateChangesBenefitObligation	228000	usd
CY2023Q4	us-gaap	Defined Benefit Plan Benefit Obligation DefinedBenefitPlanBenefitObligation	11101000	usd
CY2022Q4	us-gaap	Defined Benefit Plan Benefit Obligation DefinedBenefitPlanBenefitObligation	12685000	usd
CY2022Q4	us-gaap	Defined Benefit Plan Fair Value Of Plan Assets DefinedBenefitPlanFairValueOfPlanAssets	12640000	usd
CY2021Q4	us-gaap	Defined Benefit Plan Fair Value Of Plan Assets DefinedBenefitPlanFairValueOfPlanAssets	11267000	usd
CY2023	us-gaap	Defined Benefit Plan Actual Return On Plan Assets DefinedBenefitPlanActualReturnOnPlanAssets	58000	usd
CY2022	us-gaap	Defined Benefit Plan Actual Return On Plan Assets DefinedBenefitPlanActualReturnOnPlanAssets	111000	usd
CY2023	us-gaap	Defined Benefit Plan Contributions By Employer DefinedBenefitPlanContributionsByEmployer	700000	usd
CY2022	us-gaap	Defined Benefit Plan Contributions By Employer DefinedBenefitPlanContributionsByEmployer	968000	usd
CY2023	us-gaap	Defined Benefit Plan Plan Assets Contributions By Plan Participant DefinedBenefitPlanPlanAssetsContributionsByPlanParticipant	421000	usd
CY2022	us-gaap	Defined Benefit Plan Plan Assets Contributions By Plan Participant DefinedBenefitPlanPlanAssetsContributionsByPlanParticipant	466000	usd
CY2023	adc	Defined Benefit Plan Plan Assets Benefits Paid Credited DefinedBenefitPlanPlanAssetsBenefitsPaidCredited	100000	usd
CY2022	adc	Defined Benefit Plan Plan Assets Benefits Paid Credited DefinedBenefitPlanPlanAssetsBenefitsPaidCredited	-6000	usd
CY2023	us-gaap	Defined Benefit Plan Settlements Plan Assets DefinedBenefitPlanSettlementsPlanAssets	5201000	usd
CY2022	us-gaap	Defined Benefit Plan Settlements Plan Assets DefinedBenefitPlanSettlementsPlanAssets	0	usd
CY2023	us-gaap	Defined Benefit Plan Plan Assets Foreign Currency Translation Gain Loss DefinedBenefitPlanPlanAssetsForeignCurrencyTranslationGainLoss	1391000	usd
CY2022	us-gaap	Defined Benefit Plan Plan Assets Foreign Currency Translation Gain Loss DefinedBenefitPlanPlanAssetsForeignCurrencyTranslationGainLoss	-178000	usd
CY2023Q4	us-gaap	Defined Benefit Plan Fair Value Of Plan Assets DefinedBenefitPlanFairValueOfPlanAssets	9909000	usd
CY2022Q4	us-gaap	Defined Benefit Plan Fair Value Of Plan Assets DefinedBenefitPlanFairValueOfPlanAssets	12640000	usd
CY2023Q4	us-gaap	Defined Benefit Plan Funded Status Of Plan DefinedBenefitPlanFundedStatusOfPlan	-1192000	usd
CY2022Q4	us-gaap	Defined Benefit Plan Funded Status Of Plan DefinedBenefitPlanFundedStatusOfPlan	-45000	usd
CY2023Q4	adc	Defined Benefit Plan Number Of Active Employees DefinedBenefitPlanNumberOfActiveEmployees	24	participant
CY2022Q4	adc	Defined Benefit Plan Number Of Active Employees DefinedBenefitPlanNumberOfActiveEmployees	30	participant
CY2023	us-gaap	Defined Benefit Plan Service Cost DefinedBenefitPlanServiceCost	736000	usd
CY2022	us-gaap	Defined Benefit Plan Service Cost DefinedBenefitPlanServiceCost	1234000	usd
CY2023	us-gaap	Defined Benefit Plan Interest Cost DefinedBenefitPlanInterestCost	254000	usd
CY2022	us-gaap	Defined Benefit Plan Interest Cost DefinedBenefitPlanInterestCost	53000	usd
CY2023	us-gaap	Defined Benefit Plan Expected Return On Plan Assets DefinedBenefitPlanExpectedReturnOnPlanAssets	298000	usd
CY2022	us-gaap	Defined Benefit Plan Expected Return On Plan Assets DefinedBenefitPlanExpectedReturnOnPlanAssets	166000	usd
CY2023	us-gaap	Defined Benefit Plan Amortization Of Prior Service Cost Credit DefinedBenefitPlanAmortizationOfPriorServiceCostCredit	-160000	usd
CY2022	us-gaap	Defined Benefit Plan Amortization Of Prior Service Cost Credit DefinedBenefitPlanAmortizationOfPriorServiceCostCredit	-133000	usd
CY2023	us-gaap	Defined Benefit Plan Amortization Of Gains Losses DefinedBenefitPlanAmortizationOfGainsLosses	0	usd
CY2022	us-gaap	Defined Benefit Plan Amortization Of Gains Losses DefinedBenefitPlanAmortizationOfGainsLosses	-179000	usd
CY2023	us-gaap	Defined Benefit Plan Recognized Net Gain Loss Due To Settlements And Curtailments1 DefinedBenefitPlanRecognizedNetGainLossDueToSettlementsAndCurtailments1	79000	usd
CY2022	us-gaap	Defined Benefit Plan Recognized Net Gain Loss Due To Settlements And Curtailments1 DefinedBenefitPlanRecognizedNetGainLossDueToSettlementsAndCurtailments1	0	usd
CY2023	adc	Defined Benefit Plan Amortization Of Prior Service Cost Credit Due To Reduction In Service Years DefinedBenefitPlanAmortizationOfPriorServiceCostCreditDueToReductionInServiceYears	-244000	usd
CY2022	adc	Defined Benefit Plan Amortization Of Prior Service Cost Credit Due To Reduction In Service Years DefinedBenefitPlanAmortizationOfPriorServiceCostCreditDueToReductionInServiceYears	0	usd
CY2023	us-gaap	Defined Benefit Plan Net Periodic Benefit Cost DefinedBenefitPlanNetPeriodicBenefitCost	209000	usd
CY2022	us-gaap	Defined Benefit Plan Net Periodic Benefit Cost DefinedBenefitPlanNetPeriodicBenefitCost	1167000	usd
CY2023	us-gaap	Defined Benefit Plan Assumptions Used Calculating Net Periodic Benefit Cost Discount Rate DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostDiscountRate	0.0145
CY2022	us-gaap	Defined Benefit Plan Assumptions Used Calculating Net Periodic Benefit Cost Discount Rate DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostDiscountRate	0.0230
CY2023	us-gaap	Defined Benefit Plan Assumptions Used Calculating Net Periodic Benefit Cost Weighted Average Interest Crediting Rate DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostWeightedAverageInterestCreditingRate	0.0145
CY2022	us-gaap	Defined Benefit Plan Assumptions Used Calculating Net Periodic Benefit Cost Weighted Average Interest Crediting Rate DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostWeightedAverageInterestCreditingRate	0.0230
CY2023	us-gaap	Defined Benefit Plan Assumptions Used Calculating Net Periodic Benefit Cost Rate Of Compensation Increase DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostRateOfCompensationIncrease	0.0150
CY2022	us-gaap	Defined Benefit Plan Assumptions Used Calculating Net Periodic Benefit Cost Rate Of Compensation Increase DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostRateOfCompensationIncrease	0.0150
CY2023	adc	Defined Benefit Plan Assumptions Used Calculating Net Periodic Benefit Cost Rate Of Pension Increase DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostRateOfPensionIncrease	0.0000
CY2022	adc	Defined Benefit Plan Assumptions Used Calculating Net Periodic Benefit Cost Rate Of Pension Increase DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostRateOfPensionIncrease	0.0000
CY2023	us-gaap	Defined Benefit Plan Assumptions Used Calculating Net Periodic Benefit Cost Expected Long Term Return On Assets DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostExpectedLongTermReturnOnAssets	0.0256
CY2022	us-gaap	Defined Benefit Plan Assumptions Used Calculating Net Periodic Benefit Cost Expected Long Term Return On Assets DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostExpectedLongTermReturnOnAssets	0.0256
CY2023Q4	us-gaap	Defined Benefit Plan Expected Future Employer Contributions Next Fiscal Year DefinedBenefitPlanExpectedFutureEmployerContributionsNextFiscalYear	701000	usd
CY2023	adc	Defined Benefit Plan Obligation Weighted Average Duration DefinedBenefitPlanObligationWeightedAverageDuration	P18Y
CY2022	adc	Defined Benefit Plan Obligation Weighted Average Duration DefinedBenefitPlanObligationWeightedAverageDuration	P16Y10M24D
CY2023Q4	us-gaap	Defined Benefit Plan Expected Future Benefit Payments Next Twelve Months DefinedBenefitPlanExpectedFutureBenefitPaymentsNextTwelveMonths	379000	usd
CY2023Q4	us-gaap	Defined Benefit Plan Expected Future Benefit Payments Year Two DefinedBenefitPlanExpectedFutureBenefitPaymentsYearTwo	386000	usd
CY2023Q4	us-gaap	Defined Benefit Plan Expected Future Benefit Payments Year Three DefinedBenefitPlanExpectedFutureBenefitPaymentsYearThree	397000	usd
CY2023Q4	us-gaap	Defined Benefit Plan Expected Future Benefit Payments Year Four DefinedBenefitPlanExpectedFutureBenefitPaymentsYearFour	431000	usd
CY2023Q4	us-gaap	Defined Benefit Plan Expected Future Benefit Payments Year Five DefinedBenefitPlanExpectedFutureBenefitPaymentsYearFive	462000	usd
CY2023Q4	us-gaap	Defined Benefit Plan Expected Future Benefit Payments Five Fiscal Years Thereafter DefinedBenefitPlanExpectedFutureBenefitPaymentsFiveFiscalYearsThereafter	2822000	usd
CY2023Q4	adc	Defined Benefit Plan Expected Future Benefit Payments DefinedBenefitPlanExpectedFutureBenefitPayments	4877000	usd
CY2022Q4	us-gaap	Accumulated Other Comprehensive Income Loss Defined Benefit Pension And Other Postretirement Plans Net Of Tax AccumulatedOtherComprehensiveIncomeLossDefinedBenefitPensionAndOtherPostretirementPlansNetOfTax	-2179000	usd
CY2021Q4	us-gaap	Accumulated Other Comprehensive Income Loss Defined Benefit Pension And Other Postretirement Plans Net Of Tax AccumulatedOtherComprehensiveIncomeLossDefinedBenefitPensionAndOtherPostretirementPlansNetOfTax	1937000	usd
CY2023	us-gaap	Other Comprehensive Income Defined Benefit Plans Net Unamortized Gain Loss Arising During Period Net Of Tax OtherComprehensiveIncomeDefinedBenefitPlansNetUnamortizedGainLossArisingDuringPeriodNetOfTax	-1483000	usd
CY2022	us-gaap	Other Comprehensive Income Defined Benefit Plans Net Unamortized Gain Loss Arising During Period Net Of Tax OtherComprehensiveIncomeDefinedBenefitPlansNetUnamortizedGainLossArisingDuringPeriodNetOfTax	4070000	usd
CY2023	us-gaap	Other Comprehensive Income Defined Benefit Plan Net Prior Service Costs Credit Arising During Period Net Of Tax OtherComprehensiveIncomeDefinedBenefitPlanNetPriorServiceCostsCreditArisingDuringPeriodNetOfTax	371000	usd
CY2022	us-gaap	Other Comprehensive Income Defined Benefit Plan Net Prior Service Costs Credit Arising During Period Net Of Tax OtherComprehensiveIncomeDefinedBenefitPlanNetPriorServiceCostsCreditArisingDuringPeriodNetOfTax	-46000	usd
CY2023	us-gaap	Other Comprehensive Income Defined Benefit Plans Adjustment Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeDefinedBenefitPlansAdjustmentNetOfTaxPortionAttributableToParent	1854000	usd
CY2022	us-gaap	Other Comprehensive Income Defined Benefit Plans Adjustment Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeDefinedBenefitPlansAdjustmentNetOfTaxPortionAttributableToParent	-4116000	usd
CY2023Q4	us-gaap	Accumulated Other Comprehensive Income Loss Defined Benefit Pension And Other Postretirement Plans Net Of Tax AccumulatedOtherComprehensiveIncomeLossDefinedBenefitPensionAndOtherPostretirementPlansNetOfTax	-325000	usd
CY2022Q4	us-gaap	Accumulated Other Comprehensive Income Loss Defined Benefit Pension And Other Postretirement Plans Net Of Tax AccumulatedOtherComprehensiveIncomeLossDefinedBenefitPensionAndOtherPostretirementPlansNetOfTax	-2179000	usd
CY2023	us-gaap	Defined Benefit Plan Plan Amendments DefinedBenefitPlanPlanAmendments	-33000	usd
CY2022	us-gaap	Defined Benefit Plan Plan Amendments DefinedBenefitPlanPlanAmendments	-179000	usd
CY2023Q4	us-gaap	Purchase Commitment Remaining Minimum Amount Committed PurchaseCommitmentRemainingMinimumAmountCommitted	5000000.0	usd
CY2023	adc	Capital Stock Authorized Increase Decrease CapitalStockAuthorizedIncreaseDecrease	44520973	shares
CY2023Q4	adc	Capital Stock Par Or Stated Value Per Share CapitalStockParOrStatedValuePerShare	0.08
CY2023	adc	Capital Stock Authorized Increase To Prevent Changes In Control Maximum Amount CapitalStockAuthorizedIncreaseToPreventChangesInControlMaximumAmount	1432776	chf
CY2023	adc	Capital Stock Authorized Increase To Prevent Changes In Control Maximum Shares CapitalStockAuthorizedIncreaseToPreventChangesInControlMaximumShares	17909703	shares
CY2023Q4	adc	Capital Stock Par Or Stated Value Per Share CapitalStockParOrStatedValuePerShare	0.08
CY2023	adc	Share Based Compensation Arrangement By Share Based Payment Award Value Of Additional Shares Authorized ShareBasedCompensationArrangementByShareBasedPaymentAwardValueOfAdditionalSharesAuthorized	936000	chf
CY2023	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Number Of Additional Shares Authorized ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized	11700000	shares
CY2023Q4	adc	Capital Stock Par Or Stated Value Per Share CapitalStockParOrStatedValuePerShare	0.08
CY2022Q3	us-gaap	Sale Of Stock Number Of Shares Issued In Transaction SaleOfStockNumberOfSharesIssuedInTransaction	3123865	shares
CY2022Q4	us-gaap	Sale Of Stock Number Of Shares Issued In Transaction SaleOfStockNumberOfSharesIssuedInTransaction	7648081	shares
CY2021Q2	adc	Sale Of Stock Aggregate Offering Price SaleOfStockAggregateOfferingPrice	200000000.0	usd
CY2022Q3	us-gaap	Sale Of Stock Number Of Shares Issued In Transaction SaleOfStockNumberOfSharesIssuedInTransaction	733568	shares
CY2022Q3	us-gaap	Sale Of Stock Price Per Share SaleOfStockPricePerShare	8.52
CY2022Q3	us-gaap	Sale Of Stock Consideration Received On Transaction SaleOfStockConsiderationReceivedOnTransaction	6100000	usd
CY2022Q3	us-gaap	Stock Issued During Period Value Conversion Of Convertible Securities StockIssuedDuringPeriodValueConversionOfConvertibleSecurities	19600000	usd
CY2022Q3	us-gaap	Stock Issued During Period Shares Conversion Of Convertible Securities StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities	2390297	shares
CY2023	us-gaap	Revenues Revenues	69558000	usd
CY2022	us-gaap	Revenues Revenues	209908000	usd
CY2023	us-gaap	Revenues Revenues	69558000	usd
CY2022	us-gaap	Revenues Revenues	209908000	usd
CY2021Q4	adc	Gross To Net Sales Adjustment GrossToNetSalesAdjustment	2590000	usd
CY2022	adc	Gross To Net Sales Adjustment Provision GrossToNetSalesAdjustmentProvision	15200000	usd
CY2022	adc	Gross To Net Sales Adjustment Prior Period Adjustment GrossToNetSalesAdjustmentPriorPeriodAdjustment	-549000	usd
CY2022	adc	Gross To Net Sales Adjustment Credits And Payments GrossToNetSalesAdjustmentCreditsAndPayments	-13495000	usd
CY2022Q4	adc	Gross To Net Sales Adjustment GrossToNetSalesAdjustment	3746000	usd
CY2023	adc	Gross To Net Sales Adjustment Provision GrossToNetSalesAdjustmentProvision	24554000	usd
CY2023	adc	Gross To Net Sales Adjustment Prior Period Adjustment GrossToNetSalesAdjustmentPriorPeriodAdjustment	-1028000	usd
CY2023	adc	Gross To Net Sales Adjustment Credits And Payments GrossToNetSalesAdjustmentCreditsAndPayments	-15935000	usd
CY2023Q4	adc	Gross To Net Sales Adjustment GrossToNetSalesAdjustment	11337000	usd
CY2023Q4	adc	Trade And Other Current Receivables Sales Adjustment TradeAndOtherCurrentReceivablesSalesAdjustment	2403000	usd
CY2022Q4	adc	Trade And Other Current Receivables Sales Adjustment TradeAndOtherCurrentReceivablesSalesAdjustment	2151000	usd
CY2023Q4	adc	Current And Accrued Expenses And Other Current Liabilities Sales Adjustment CurrentAndAccruedExpensesAndOtherCurrentLiabilitiesSalesAdjustment	8934000	usd
CY2022Q4	adc	Current And Accrued Expenses And Other Current Liabilities Sales Adjustment CurrentAndAccruedExpensesAndOtherCurrentLiabilitiesSalesAdjustment	1595000	usd
CY2023Q4	adc	Gross To Net Sales Adjustment GrossToNetSalesAdjustment	11337000	usd
CY2022Q4	adc	Gross To Net Sales Adjustment GrossToNetSalesAdjustment	3746000	usd
CY2022Q1	adc	Proceeds From License Arrangement ProceedsFromLicenseArrangement	30000000	usd
CY2022Q1	adc	License Agreement Milestone Payments LicenseAgreementMilestonePayments	205000000	usd
CY2022Q3	adc	Proceeds From License Arrangement ProceedsFromLicenseArrangement	55000000	usd
CY2022Q3	adc	License Agreement Milestone Payments LicenseAgreementMilestonePayments	382500000	usd
CY2022	adc	License Agreement Revenue Recognized LicenseAgreementRevenueRecognized	50000000	usd
CY2023	us-gaap	Investment Income Interest And Dividend InvestmentIncomeInterestAndDividend	10500000	usd
CY2022	us-gaap	Investment Income Interest And Dividend InvestmentIncomeInterestAndDividend	2600000	usd
CY2023	adc	Deferred Royalty Obligation Interest Expense DeferredRoyaltyObligationInterestExpense	27915000	usd
CY2022	adc	Deferred Royalty Obligation Interest Expense DeferredRoyaltyObligationInterestExpense	23200000	usd
CY2023	us-gaap	Interest Expense Other InterestExpenseOther	12000	usd
CY2022	us-gaap	Interest Expense Other InterestExpenseOther	2000	usd
CY2023	us-gaap	Interest Expense InterestExpense	46325000	usd
CY2022	us-gaap	Interest Expense InterestExpense	36731000	usd
CY2022	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt	-42100000	usd
CY2023	us-gaap	Derivative Gain Loss On Derivative Net DerivativeGainLossOnDerivativeNet	0	usd
CY2022	us-gaap	Derivative Gain Loss On Derivative Net DerivativeGainLossOnDerivativeNet	25650000	usd
CY2023	adc	Deferred Royalty Obligation Cumulative Catch Up Adjustment DeferredRoyaltyObligationCumulativeCatchUpAdjustment	-4972000	usd
CY2022	adc	Deferred Royalty Obligation Cumulative Catch Up Adjustment DeferredRoyaltyObligationCumulativeCatchUpAdjustment	-15402000	usd
CY2023	us-gaap	Foreign Currency Transaction Gain Loss Before Tax ForeignCurrencyTransactionGainLossBeforeTax	-52000	usd
CY2022	us-gaap	Foreign Currency Transaction Gain Loss Before Tax ForeignCurrencyTransactionGainLossBeforeTax	-109000	usd
CY2023	adc	Research And Development Tax Credit ResearchAndDevelopmentTaxCredit	-935000	usd
CY2022	adc	Research And Development Tax Credit ResearchAndDevelopmentTaxCredit	-357000	usd
CY2023	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	6352000	usd
CY2022	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	52804000	usd
CY2022Q3	us-gaap	Debt Conversion Converted Instrument Warrants Or Options Issued1 DebtConversionConvertedInstrumentWarrantsOrOptionsIssued1	4412840	shares
CY2022Q3	us-gaap	Debt Conversion Converted Instrument Shares Issued1 DebtConversionConvertedInstrumentSharesIssued1	2390297	shares
CY2022Q3	us-gaap	Debt Conversion Converted Instrument Warrants Or Options Issued1 DebtConversionConvertedInstrumentWarrantsOrOptionsIssued1	4412840	shares
CY2021Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	27.23
CY2021Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	6640200	shares
CY2021	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2	P8Y8M12D
CY2022	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice	9.63
CY2022	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross	5754786	shares
CY2022	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice	23.27
CY2022	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod	1358167	shares
CY2022	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Expirations In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice	27.53
CY2022	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Expirations In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod	281325	shares
CY2022Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	18.30
CY2022Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	10755494	shares
CY2022	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2	P8Y5M15D
CY2023	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice	2.20
CY2023	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross	3900341	shares
CY2023	adc	Share Based Compensation Arrangements By Share Based Payment Award Options Exchange Grants In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExchangeGrantsInPeriodWeightedAverageExercisePrice	2.06
CY2023	adc	Share Based Compensation Arrangement By Share Based Payment Award Options Exchange Grants In Period Gross ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExchangeGrantsInPeriodGross	898585	shares
CY2023	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice	12.58
CY2023	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod	1668740	shares
CY2023	adc	Share Based Compensation Arrangements By Share Based Payment Award Options Exchange Forfeitures In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExchangeForfeituresInPeriodWeightedAverageExercisePrice	22.55
CY2023	adc	Share Based Compensation Arrangement By Share Based Payment Award Options Exchange Forfeitures In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExchangeForfeituresInPeriod	2197458	shares
CY2023	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Expirations In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice	22.09
CY2023	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Expirations In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod	943816	shares
CY2023Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	11.00
CY2023Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	10744406	shares
CY2023	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2	P8Y1M20D
CY2023Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Exercisable Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber	4132591	shares
CY2023Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	10744406	shares
CY2023Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Exercisable Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice	21.35
CY2023	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1	P7Y1M28D
CY2023Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice	1.53
CY2022Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice	6.24
CY2023Q4	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Nonvested Number Of Shares SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares	6611815	shares
CY2023Q4	us-gaap	Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Stock Options EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions	12900000	usd
CY2023	us-gaap	Net Income Loss NetIncomeLoss	-240053000	usd
CY2022	us-gaap	Net Income Loss NetIncomeLoss	-157128000	usd
CY2023	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	81712166	shares
CY2023	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	81712166	shares
CY2022	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	78152964	shares
CY2022	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	78152964	shares
CY2023	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-2.94
CY2023	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-2.94
CY2022	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-2.01
CY2022	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-2.01
CY2023	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	22448059	shares
CY2022	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	17411854	shares
CY2023Q4	ecd	Rule10b51 Arr Adopted Flag Rule10b51ArrAdoptedFlag	false
CY2023Q4	ecd	Non Rule10b51 Arr Adopted Flag NonRule10b51ArrAdoptedFlag	false
CY2023Q4	ecd	Non Rule10b51 Arr Trmntd Flag NonRule10b51ArrTrmntdFlag	false
CY2023Q4	ecd	Rule10b51 Arr Trmntd Flag Rule10b51ArrTrmntdFlag	false

Files In Submission

Name	View Source	Status
0001628280-24-010843-index-headers.html	Edgar Link	pending
0001628280-24-010843-index.html	Edgar Link	pending
0001628280-24-010843.txt	Edgar Link	pending
0001628280-24-010843-xbrl.zip	Edgar Link	pending
adc-20231231.htm	Edgar Link	pending
adc-20231231.xsd	Edgar Link	pending
adc-20231231_g1.jpg	Edgar Link	pending
adc-20231231_g2.jpg	Edgar Link	pending
adc-20231231_g3.jpg	Edgar Link	pending
ex311-ceocertification302.htm	Edgar Link	pending
ex312-cfocertification302.htm	Edgar Link	pending
ex321-ceocertification906.htm	Edgar Link	pending
adc-20231231_cal.xml	Edgar Link	unprocessable
adc-20231231_def.xml	Edgar Link	unprocessable
adc-20231231_lab.xml	Edgar Link	unprocessable
adc-20231231_pre.xml	Edgar Link	unprocessable
adc-20231231_htm.xml	Edgar Link	completed
ex322-cfocertification906.htm	Edgar Link	pending
exhibit1012formofawardagre.htm	Edgar Link	pending
exhibit1014formofawardagre.htm	Edgar Link	pending
exhibit1017executiveempl.htm	Edgar Link	pending
exhibit1017executiveempl001.jpg	Edgar Link	pending
exhibit1017executiveempl002.jpg	Edgar Link	pending
exhibit1017executiveempl003.jpg	Edgar Link	pending
exhibit1017executiveempl004.jpg	Edgar Link	pending
exhibit1017executiveempl005.jpg	Edgar Link	pending
exhibit1017executiveempl006.jpg	Edgar Link	pending
exhibit1017executiveempl007.jpg	Edgar Link	pending
exhibit1017executiveempl008.jpg	Edgar Link	pending
exhibit1017executiveempl009.jpg	Edgar Link	pending
exhibit1017executiveempl010.jpg	Edgar Link	pending
exhibit1017executiveempl011.jpg	Edgar Link	pending
exhibit1017executiveempl012.jpg	Edgar Link	pending
exhibit1017executiveempl013.jpg	Edgar Link	pending
exhibit1017executiveempl014.jpg	Edgar Link	pending
exhibit1018amendmenttoex.htm	Edgar Link	pending
exhibit1018amendmenttoex001.jpg	Edgar Link	pending
exhibit1018amendmenttoex002.jpg	Edgar Link	pending
exhibit1018amendmenttoex003.jpg	Edgar Link	pending
exhibit1018amendmenttoex004.jpg	Edgar Link	pending
exhibit1018amendmenttoex005.jpg	Edgar Link	pending
exhibit1019retentionbonu.htm	Edgar Link	pending
exhibit1019retentionbonu001.jpg	Edgar Link	pending
exhibit1019retentionbonu002.jpg	Edgar Link	pending
exhibit1019retentionbonu003.jpg	Edgar Link	pending
exhibit1019retentionbonu004.jpg	Edgar Link	pending
exhibit1020employmentagr.htm	Edgar Link	pending
exhibit1020employmentagr001.jpg	Edgar Link	pending
exhibit1020employmentagr002.jpg	Edgar Link	pending
exhibit1020employmentagr003.jpg	Edgar Link	pending
exhibit1020employmentagr004.jpg	Edgar Link	pending
exhibit1020employmentagr005.jpg	Edgar Link	pending
exhibit1020employmentagr006.jpg	Edgar Link	pending
exhibit1020employmentagr007.jpg	Edgar Link	pending
exhibit1020employmentagr008.jpg	Edgar Link	pending
exhibit1020employmentagr009.jpg	Edgar Link	pending
exhibit1020employmentagr010.jpg	Edgar Link	pending
exhibit1020employmentagr011.jpg	Edgar Link	pending
exhibit1020employmentagr012.jpg	Edgar Link	pending
exhibit1020employmentagr013.jpg	Edgar Link	pending
exhibit1021retentionbonu.htm	Edgar Link	pending
exhibit1021retentionbonu001.jpg	Edgar Link	pending
exhibit1021retentionbonu002.jpg	Edgar Link	pending
exhibit1021retentionbonu003.jpg	Edgar Link	pending
exhibit1021retentionbonu004.jpg	Edgar Link	pending
exhibit1022employmentagr.htm	Edgar Link	pending
exhibit1022employmentagr001.jpg	Edgar Link	pending
exhibit1022employmentagr002.jpg	Edgar Link	pending
exhibit1022employmentagr003.jpg	Edgar Link	pending
exhibit1022employmentagr004.jpg	Edgar Link	pending
exhibit1022employmentagr005.jpg	Edgar Link	pending
exhibit1022employmentagr006.jpg	Edgar Link	pending
exhibit1022employmentagr007.jpg	Edgar Link	pending
exhibit1022employmentagr008.jpg	Edgar Link	pending
exhibit1022employmentagr009.jpg	Edgar Link	pending
exhibit1022employmentagr010.jpg	Edgar Link	pending
exhibit1022employmentagr011.jpg	Edgar Link	pending
exhibit1022employmentagr012.jpg	Edgar Link	pending
exhibit1022employmentagr013.jpg	Edgar Link	pending
exhibit1022employmentagr014.jpg	Edgar Link	pending
exhibit1022employmentagr015.jpg	Edgar Link	pending
exhibit1022employmentagr016.jpg	Edgar Link	pending
exhibit1023employmentagr.htm	Edgar Link	pending
exhibit1023employmentagr001.jpg	Edgar Link	pending
exhibit1023employmentagr002.jpg	Edgar Link	pending
exhibit1023employmentagr003.jpg	Edgar Link	pending
exhibit1023employmentagr004.jpg	Edgar Link	pending
exhibit1023employmentagr005.jpg	Edgar Link	pending
exhibit1023employmentagr006.jpg	Edgar Link	pending
exhibit1023employmentagr007.jpg	Edgar Link	pending
exhibit1023employmentagr008.jpg	Edgar Link	pending
exhibit1023employmentagr009.jpg	Edgar Link	pending
exhibit1023employmentagr010.jpg	Edgar Link	pending
exhibit1023employmentagr011.jpg	Edgar Link	pending
exhibit1023employmentagr012.jpg	Edgar Link	pending
exhibit1023employmentagr013.jpg	Edgar Link	pending
exhibit1023employmentagr014.jpg	Edgar Link	pending
exhibit1023employmentagr015.jpg	Edgar Link	pending
exhibit1023employmentagr016.jpg	Edgar Link	pending
exhibit1023employmentagr017.jpg	Edgar Link	pending
exhibit1023employmentagr018.jpg	Edgar Link	pending
exhibit1023employmentagr019.jpg	Edgar Link	pending
exhibit1023employmentagr020.jpg	Edgar Link	pending
exhibit1023employmentagr021.jpg	Edgar Link	pending
exhibit1023employmentagr022.jpg	Edgar Link	pending
exhibit1023employmentagr023.jpg	Edgar Link	pending
exhibit1023employmentagr024.jpg	Edgar Link	pending
exhibit1023employmentagr025.jpg	Edgar Link	pending
exhibit1024employmenttra.htm	Edgar Link	pending
exhibit1024employmenttra001.jpg	Edgar Link	pending
exhibit1024employmenttra002.jpg	Edgar Link	pending
exhibit1024employmenttra003.jpg	Edgar Link	pending
exhibit1024employmenttra004.jpg	Edgar Link	pending
exhibit1025employmentagr.htm	Edgar Link	pending
exhibit1025employmentagr001.jpg	Edgar Link	pending
exhibit1025employmentagr002.jpg	Edgar Link	pending
exhibit1025employmentagr003.jpg	Edgar Link	pending
exhibit1025employmentagr004.jpg	Edgar Link	pending
exhibit1025employmentagr005.jpg	Edgar Link	pending
exhibit1025employmentagr006.jpg	Edgar Link	pending
exhibit1025employmentagr007.jpg	Edgar Link	pending
exhibit1025employmentagr008.jpg	Edgar Link	pending
exhibit1025employmentagr009.jpg	Edgar Link	pending
exhibit1025employmentagr010.jpg	Edgar Link	pending
exhibit1025employmentagr011.jpg	Edgar Link	pending
exhibit1026employmenttra.htm	Edgar Link	pending
exhibit1026employmenttra001.jpg	Edgar Link	pending
exhibit1026employmenttra002.jpg	Edgar Link	pending
exhibit1027employmenttra.htm	Edgar Link	pending
exhibit1027employmenttra001.jpg	Edgar Link	pending
exhibit1027employmenttra002.jpg	Edgar Link	pending
exhibit1027employmenttra003.jpg	Edgar Link	pending
exhibit1028letteragreement.htm	Edgar Link	pending
exhibit1029chrismartinco.htm	Edgar Link	pending
exhibit1029chrismartinco001.jpg	Edgar Link	pending
exhibit1029chrismartinco002.jpg	Edgar Link	pending
exhibit1029chrismartinco003.jpg	Edgar Link	pending
exhibit1030consutlingagr.htm	Edgar Link	pending
exhibit1030consutlingagr001.jpg	Edgar Link	pending
exhibit1030consutlingagr002.jpg	Edgar Link	pending
exhibit1030consutlingagr003.jpg	Edgar Link	pending
exhibit1030consutlingagr004.jpg	Edgar Link	pending
exhibit1030consutlingagr005.jpg	Edgar Link	pending
exhibit1030consutlingagr006.jpg	Edgar Link	pending
exhibit1030consutlingagr007.jpg	Edgar Link	pending
exhibit1030consutlingagr008.jpg	Edgar Link	pending
exhibit1030consutlingagr009.jpg	Edgar Link	pending
exhibit1082limitedwaiver.htm	Edgar Link	pending
exhibit1082limitedwaiver001.jpg	Edgar Link	pending
exhibit1082limitedwaiver002.jpg	Edgar Link	pending
exhibit1082limitedwaiver003.jpg	Edgar Link	pending
exhibit1082limitedwaiver004.jpg	Edgar Link	pending
exhibit1082limitedwaiver005.jpg	Edgar Link	pending
exhibit1082limitedwaiver006.jpg	Edgar Link	pending
exhibit1082limitedwaiver007.jpg	Edgar Link	pending
exhibit1082limitedwaiver008.jpg	Edgar Link	pending
exhibit1082limitedwaiver009.jpg	Edgar Link	pending
exhibit1082limitedwaiver010.jpg	Edgar Link	pending
exhibit1082limitedwaiver011.jpg	Edgar Link	pending
exhibit1082limitedwaiver012.jpg	Edgar Link	pending
exhibit1082limitedwaiver013.jpg	Edgar Link	pending
exhibit1082limitedwaiver014.jpg	Edgar Link	pending
exhibit231consentletterofp.htm	Edgar Link	pending
exhibit41descriptionofsecu.htm	Edgar Link	pending
exhibit971clawbackpolicy.htm	Edgar Link	pending
Financial_Report.xlsx	Edgar Link	pending
image_0.jpg	Edgar Link	pending
image_0b.jpg	Edgar Link	pending
image_15.jpg	Edgar Link	pending
MetaLinks.json	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R100.htm	Edgar Link	pending
R101.htm	Edgar Link	pending
R102.htm	Edgar Link	pending
R103.htm	Edgar Link	pending
R104.htm	Edgar Link	pending
R105.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R43.htm	Edgar Link	pending
R44.htm	Edgar Link	pending
R45.htm	Edgar Link	pending
R46.htm	Edgar Link	pending
R47.htm	Edgar Link	pending
R48.htm	Edgar Link	pending
R49.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R50.htm	Edgar Link	pending
R51.htm	Edgar Link	pending
R52.htm	Edgar Link	pending
R53.htm	Edgar Link	pending
R54.htm	Edgar Link	pending
R55.htm	Edgar Link	pending
R56.htm	Edgar Link	pending
R57.htm	Edgar Link	pending
R58.htm	Edgar Link	pending
R59.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R60.htm	Edgar Link	pending
R61.htm	Edgar Link	pending
R62.htm	Edgar Link	pending
R63.htm	Edgar Link	pending
R64.htm	Edgar Link	pending
R65.htm	Edgar Link	pending
R66.htm	Edgar Link	pending
R67.htm	Edgar Link	pending
R68.htm	Edgar Link	pending
R69.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R70.htm	Edgar Link	pending
R71.htm	Edgar Link	pending
R72.htm	Edgar Link	pending
R73.htm	Edgar Link	pending
R74.htm	Edgar Link	pending
R75.htm	Edgar Link	pending
R76.htm	Edgar Link	pending
R77.htm	Edgar Link	pending
R78.htm	Edgar Link	pending
R79.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R80.htm	Edgar Link	pending
R81.htm	Edgar Link	pending
R82.htm	Edgar Link	pending
R83.htm	Edgar Link	pending
R84.htm	Edgar Link	pending
R85.htm	Edgar Link	pending
R86.htm	Edgar Link	pending
R87.htm	Edgar Link	pending
R88.htm	Edgar Link	pending
R89.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
R90.htm	Edgar Link	pending
R91.htm	Edgar Link	pending
R92.htm	Edgar Link	pending
R93.htm	Edgar Link	pending
R94.htm	Edgar Link	pending
R95.htm	Edgar Link	pending
R96.htm	Edgar Link	pending
R97.htm	Edgar Link	pending
R98.htm	Edgar Link	pending
R99.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending
FilingSummary.xml	Edgar Link	unprocessable

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$ADCT
ADC Therapeutics SA Stock $adct

2024 Q1 Form 10-K Financial Statement

#000162828024010843 Filed on March 13, 2024

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$ADCT ADC Therapeutics SA Stock $adct

2024 Q1 Form 10-K Financial Statement

#000162828024010843 Filed on March 13, 2024

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$ADCT
ADC Therapeutics SA Stock $adct